Regeneron Pharmaceuticals, Inc.
REGN
$718.16
-$26.67-3.58%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 4.41B | 4.65B | 4.32B | 3.86B | 3.95B |
| Total Depreciation and Amortization | 482.90M | 469.50M | 453.20M | 435.60M | 421.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 143.30M | -283.30M | 17.30M | 340.00M | 313.50M |
| Change in Net Operating Assets | -618.30M | -593.30M | -721.70M | 105.50M | -94.10M |
| Cash from Operations | 4.42B | 4.25B | 4.07B | 4.74B | 4.59B |
| Capital Expenditure | -755.90M | -807.70M | -741.80M | -674.30M | -718.60M |
| Sale of Property, Plant, and Equipment | 20.10M | 20.10M | 20.10M | -- | -- |
| Cash Acquisitions | -16.50M | -8.80M | -59.90M | -54.90M | -54.90M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.72B | -2.09B | -2.03B | -3.91B | -2.41B |
| Cash from Investing | -2.47B | -2.88B | -2.81B | -4.64B | -3.19B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.47B | 1.68B | 1.69B | 1.34B | 1.15B |
| Repurchase of Common Stock | -3.63B | -3.15B | -2.97B | -2.76B | -2.94B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -33.40M | -33.40M | -- | -- | -- |
| Cash from Financing | -2.20B | -1.51B | -1.28B | -1.42B | -1.79B |
| Foreign Exchange rate Adjustments | -700.00K | 200.00K | -800.00K | -900.00K | -400.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -248.80M | -148.40M | -21.50M | -1.32B | -381.60M |
